Results 21 to 30 of about 11,053 (191)
PLoS ONE, 2021 ObjectivesComprehensive cost-effectiveness analyses of introducing varicella and/or herpes zoster vaccination in the Swedish national vaccination programme.DesignCost-effectiveness analyses based on epidemiological results from a specifically developed ...
Ellen Wolff +5 more
doaj +1 more source
Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. [PDF]
, 2001 Many countries are currently studying the possibility of mass vaccination against varicella. The objective of this study was to provide a comprehensive picture of the pre-vaccine epidemiology of the varicella zoster virus (VZV) to aid in the design of ...
Edmunds, WJ +7 more
core +1 more source
Zoster Meningitis in an Immunocompetent Child after COVID-19 Vaccination, California, USA
Emerging Infectious Diseases, 2022 Varicella zoster virus reactivation after COVID-19 vaccination has been reported in older or immunocompromised adults. We report zoster meningitis from live-attenuated varicella vaccine reactivation in an immunocompetent child after COVID-19 vaccination.
Sarah K. Daouk +3 more
doaj +1 more source
Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence
BMC Medicine, 2018 de Boer and colleagues present a cost-effectiveness analysis based in the Netherlands of two vaccines available for the prevention of herpes zoster. Zostavax® was the first vaccine available for the prevention of herpes zoster in older adults.
Chester B. Good +2 more
doaj +1 more source
Varicella Zoster vaccination in hemodialysis patients: The state of the art
Human Vaccines & Immunotherapeutics, 2023 Varicella Zoster Virus (VZV) infection is a common childhood exanthematous disease, which in adults and immunocompromised people may result in severe neurologic complications.
Laura Gobbi +4 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2021 Varicella live attenuated vaccine led to a significant reduction in morbidity and mortality from varicella zoster disease. Vaccine adverse effects are mostly mild. Immunosuppression is the main risk factor for severe varicella.
Rana Swed-Tobia +5 more
doaj +1 more source
Cost-effectiveness of herpes zoster vaccines in the U.S.: A systematic review
Preventive Medicine Reports, 2022 The purpose of this study was to conduct a systematic review to evaluate the cost-effectiveness evidence of herpes zoster vaccines in the U.S. A systematic literature review was undertaken for U.S.
Neil R. Meredith, Edward P. Armstrong
doaj +1 more source
Viruses, 2020 Varicella vaccine is a live attenuated varicella-zoster virus (VZV). Like its parental strain called VZV pOka, the vaccine virus vOka retains some neurotropic properties.
Ethan H. Heusel, Charles Grose
doaj +1 more source
The epidemiology of Herpes zoster in an urban population [PDF]
A community-based case-control study was carried out in South London, to investigate the determinants of herpes zoster in adults without underlying immunosuppression.
Thomas, Sara Loraine Monro
core +1 more source
, 2023 Background. The risk of herpes zoster reactivation is increased in immunocompromised patients, especially in those with immune-mediated inflammatory diseases (IMIDs) on Janus kinase inhibitor (JAKi) treatment.
Santiago Munoz-Fernández +21 more
core +1 more source